Arcellx, Inc. (ACLX)
NASDAQ: ACLX · Real-Time Price · USD
75.54
+0.33 (0.44%)
Dec 20, 2024, 4:00 PM EST - Market closed
Arcellx Employees
Arcellx had 130 employees as of December 31, 2023. The number of employees increased by 32 or 32.65% compared to the previous year.
Employees
130
Change (1Y)
32
Growth (1Y)
32.65%
Revenue / Employee
$1,198,600
Profits / Employee
-$310,946
Market Cap
4.08B
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 130 | 32 | 32.65% |
Dec 31, 2022 | 98 | 20 | 25.64% |
Dec 31, 2021 | 78 | 47 | 151.61% |
Dec 31, 2019 | 31 | - | - |
Related Stocks
Company Name | Employees |
---|---|
Integer Holdings | 10,500 |
Haemonetics | 3,657 |
Guardant Health | 1,779 |
Ultragenyx Pharmaceutical | 1,276 |
Apellis Pharmaceuticals | 706 |
PROCEPT BioRobotics | 626 |
ADMA Biologics | 624 |
Prestige Consumer Healthcare | 570 |
ACLX News
- 12 days ago - Arcellx's Cancer Cell Therapy Shows Deep, Durable Responses With Manageable Safety Profile In Heavily Pretreated Blood Cancer Patients - Benzinga
- 12 days ago - Arcellx Announces New Positive Data for Its iMMagine-1 Study in Patients With Relapsed or Refractory Multiple Myeloma to be Presented During an Oral Presentation at the 66th ASH Annual Meeting and Exposition - Business Wire
- 6 weeks ago - Arcellx Provides Third Quarter 2024 Financial Results and Business Highlights - Business Wire
- 6 weeks ago - Arcellx to Present Clinical Data for Its Phase 1 and iMMagine-1 Studies in Patients with Relapsed or Refractory Multiple Myeloma at the 66th ASH Annual Meeting and Exposition and Announces Progress in iMMagine-3 Study - Business Wire
- 3 months ago - Arcellx's Anito-Cel: Compelling Opportunity As Potential Best-In-Class CAR-T Therapy For Multiple Myeloma - Seeking Alpha
- 4 months ago - Arcellx Provides Second Quarter 2024 Financial Results and Business Updates - Business Wire
- 6 months ago - Arcellx's Strategic Moves With Anito-Cel Aim To Disrupt Myeloma Market - Seeking Alpha
- 8 months ago - Arcellx and Kite Continue Momentum with Advances in Anito-Cel Multiple Myeloma Program - Business Wire